Session Details

Quality & Operations Track Session 3 - Stability
Friday, September 13, 2019 03:30 PM - 05:00 PM
Ballroom B
Stability programs are mandated by multiple accreditation agencies. However, guidelines are often broad, creating a wide spectrum of interpretation and execution based on the capabilities of each institution. This session will serve as a catalyst for addressing these challenges through discussion and collegial experience.
Progress updates from the AABB-ISCT Joint Working Group's Stability Committee will be shared in an interactive format. Presentations on functional potency and real world stability program development will be disseminated. Audience participation will be utilized to fine tune a roadmap for best practices.

Chair: Karl Stasko, BSc, MPH, Dana-Farber Cancer Institute, Cell Manipulation Core Facility, USA
Speakers:
A Road Best Traveled: AABB-ISCT Joint Working Group Stability Committee Update
Karl Stasko, BSc, MPH, , Dana-Farber Cancer Institute, Cell Manipulation Core Facility, USA
Learning objectives:
•      Understand the goals of the AABB-ISCT Joint Working Group Stability Committee.
•      Understand the rationale and approach in creating a ""Roadmap"" for stability programs.
•      Discover where you fall in the stability program spectrum by reviewing survey results and participating with peers.

The CFU Assay: a biological tool to determine functional viability, potency and stability of CTPs
Jackie Damen, PhD, Senior Scientific Advisor, Hematopoiesis, Canada
Learning objectives:
•      Define the CFU assay and it's characteristics as a biological tool in identifying hematopoietic stem and progenitor cells
•      Identify publications using the CFU assay to verify the potency and stability of Hematopoietic Cellular Therapy Products
•      Understand the utility of the CFU assay in the processing and manufacturing of Hematopoietic Cellular Therapy Products